Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R-phenserine - Annovis Bio

Drug Profile

R-phenserine - Annovis Bio

Alternative Names: (+)-(3aR)-phenserine; (+)-phenserine; ANVS-401; ANVS-405; Posiphen

Latest Information Update: 02 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA); Raptor Pharmaceutical Corp
  • Developer Annovis Bio; Cenomed BioSciences; Rockefeller University; University of California at Los Angeles
  • Class Antidementias; Antidotes; Antiparkinsonians; Nootropics; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Mild cognitive impairment; Parkinson's disease
  • Phase I Down syndrome
  • Preclinical Traumatic brain injuries
  • No development reported Huntington's disease; Poisoning

Most Recent Events

  • 29 Oct 2020 Annovis Bio plans phase III trials in Alzheimer's disease
  • 29 Sep 2020 Pharmacodynamics data from preclinical trials in Down syndrome released by Annovis Bio
  • 01 Sep 2020 Annovis Bio plans a dose response study in Parkinson's disease
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top